Tagged with AstraZeneca

UK Yesterday, pharma giant AstraZeneca announced that they have halted investment in the UK due to lack of clarity on trading regulations during this time of Brexit uncertainty. “If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest,” Leif…

AstraZeneca Gwenael Meneux of AstraZeneca Hong Kong and Macau gives his initial impression of the HK market, outlines his unusual career trajectory and the new innovations AZ is looking to bring to patients in the region.   Gwenael, you have a very interesting and diverse background that is a bit atypical…

UK The UK country managers of some of the biggest global pharma companies explain what it takes to manage in the UK market.   Erik Nordkamp, Pfizer Erik Nordkamp, the Dutch national serving as managing director of Pfizer UK and the newly-appointed president of the ABPI, likens managing a UK affiliate…

UK Having recently joined the UK operations of AstraZeneca after a varied international career, Laurent Abuaf shares his vision of the UK as a life sciences reference market and his take on what makes the NHS so unique. Moreover, he highlights some exciting elements of AstraZeneca’s pipeline and reaffirms the company’s…

Lithuania With over 120,000 people whose lives are affected by the disease in Lithuania; diabetes stands as one of the country’s major health issues today. Furthermore, as Marijus Valatka, general manager for Lithuania, Latvia and Estonia of Novo Nordisk – the world leader in insulin and diabetes drugs – explains, “Lithuania…

Baltics Kuuno Vaher, market access director Baltics and country lead of AstraZeneca Estonia, discusses the liberal attitude towards innovative and highly needed medicines of Estonian regulators and the crucial importance of closer collaboration with payers, which has led the thriving affiliate to have its portfolio reimbursed in the country. Can you…

UK Much of the new inward investment in the UK from international pharmaceutical companies is from those that wish their discovery science to be in close adjacency to the most successful basic science programmes in biomedicinein the world. The co-location of pharmaceutical discovery sciences adjacent to the best universities (AstraZeneca in Cambridge, Novo Nordisk…

Pharma The top 10 pharmaceutical companies in Canada for 2016 in terms of total sales and market share. Johnson & Johnson leads the way with USD 2.93 billion in sales, followed by Novartis with USD 1.24 billion and TEVA with USD 1.19 billion.

Lithuania Martynas Jocys, Baltics marketing director and Lithuania general manager at AstraZeneca, talks about the role that innovation has played in the company’s strategy, the need for increased patient access in Lithuania and the other Baltic countries as well as the launch of new products for oncology, biologics, severe asthma, diabetes,…

Serbia By reorganizing their management structure, diversifying their offering and presenting an altogether cleaner image, AstraZeneca Serbia has made tremendous progress since its beginnings in the Balkans in the late 1990s. Country Director Ksenija Purkovic discusses the future of the Anglo-Swedish outfit, and how best to navigate a market that is…

Poland Jarek Oleszczuk, country president of AstraZeneca Poland, the leading R&D investor in Poland, discusses the exciting milestones that the company has achieved, including reimbursement of two breakthrough oncology therapies, as well as the company’s addition of 500 staff, representing now a 1,150-strong workforce. Furthermore, he touches on AstraZeneca’s key role…

Brazil Fraser Hall, country president of AstraZeneca Brazil, describes the current trends and dynamics shaping the Brazilian pharmaceutical market and documents the promising partnership opportunities he envisions to significantly increase patient access in both the private and public sectors. You were appointed country president of AstraZeneca Brazil in September 2016 after…